| Customization: | Available |
|---|---|
| CAS No.: | 171500-79-1 |
| Formula: | C88h100cl2n10o28 |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Dalbavancin
CAS: 171500-79-1
Qualification: ISO9001:2015; GMP
Overview
Dalbavancin is a new type of glycopeptide antibiotic that mainly treats skin and soft tissue infections. It has strong antibacterial activity against Gram positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), methicillin-resistant Staphylococcus aureus (MSSA), coagulase negative Staphylococcus aureus (CoNS), and G+- resistant pathogens such as penicillin resistant and ceftriaxone resistant Streptococcus pneumoniae. Dabawanxing has unique pharmacokinetic properties and can be injected once a week. Patients may not need to be hospitalized and can receive treatment in the outpatient department, which is expected to change the current treatment mode and has significant advantages.
Our Achievements and Advantages
The research team used synthetic biotechnology to reconstruct the synthetic biological system of the precursor A40926 producing strain of Dabawanxin, and obtained high-yield strains. After synthesizing precursor A40926, Dabawanxin was obtained through three steps of chemical modification (R3 amidation), with a dry content of ≥ 98% and almost no impurities of homologous substances in the raw material. The project has been granted a Chinese invention patent and has independent intellectual property rights.
Applications
Also known as dauricin, it is a novel semi synthetic glycopeptide antibiotic derived from the analogue A40926 of teicoplanin. Dalbavancin has the same mechanism of action as vancomycin and teicoplanin, inhibiting the biosynthesis of G+bacterial cell walls and is widely used as a drug for treating skin and soft tissue infections.
Storage Condition
Keep in a dark place, under an inert atmosphere, at 2-8°C.
){kind=link}